Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Hiesterman

Orthopaedic Trauma Bozeman, MT Doctor of Osteopathy

NPI 1508044421 CMS profile 158971

711 W Main St, Bozeman, MT 59715

Open in the dashboard

General payments

$8,836

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Hiesterman of Bozeman, MT is reported in the CMS Open Payments database as having received $8,836 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 2
2024 General $366 7
2023 General $1,653 15
2022 General $1,863 22
2021 General $2,274 14
2019 General $2,648 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Hiesterman
  • Orthopaedic Trauma median
  • Middle half of Orthopaedic Trauma
  • National median

In program year 2025, general payments to Timothy Hiesterman were reported at $33. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.

Show as a table
Year Timothy Hiesterman Orthopaedic Trauma median Middle half National median
2019 $2,648 $1,475 $264–$6,401 $163
2020 $0 $596 $120–$4,020 $114
2021 $2,274 $919 $171–$4,697 $132
2022 $1,863 $1,547 $272–$7,240 $149
2023 $1,653 $1,330 $247–$5,875 $160
2024 $366 $1,288 $277–$6,797 $164
2025 $33 $1,227 $259–$7,433 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $5,766 53 payments
  2. Gemini Medical LLC $1,655 5 payments
  3. Arthrex, Inc. $1,216 2 payments
  4. DePuy Synthes Sales Inc. $151 8 payments
  5. Zimmer Biomet Holdings, Inc. $30 2 payments
  6. Heron Therapeutics, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,696 13 payments
  2. Food and Beverage $2,848 56 payments
  3. Education $2,292 2 payments
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $2,897 25 payments
  2. MAKO Knees, Hips $1,556 10 payments
  3. TRIATHLON $485 5 payments
  4. T2 Trauma & Extremeties $266 1 payment
  5. PRO $209 1 payment
  6. T2 Nails $184 3 payments
  7. MAKO Joint Replacement Hips, Knees $177 2 payments
  8. GAMMA $156 2 payments
  9. T2 ALPHA $124 1 payment
  10. T2 Nails $123 1 payment
  11. Other $828 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

137

Median for Orthopedic Surgery: 203

Drug cost

$1,064

Median for Orthopedic Surgery: $1,433

Branded share of claims

32.8%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 41 $336
Ondansetron Odt Ondansetron Brand 31 $235
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $151
Cefadroxil Generic 21 $147
Celecoxib Generic 13 $126
Methocarbamol Generic 17 $69

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$55,427

Of which drugs: $102

Medicare patients

89

Average age 73

Services billed

350

62 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 54%
Depression 22%
Osteoporosis 22%
Atrial fibrillation 15%
Ischemic heart disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 26 138 $102

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Trauma in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record